Skuteczność terapii

Badania naukowe skuteczności terapii chelatowej

  1. Seven MJ. Observations on the toxicity of intravenous chelating agents. In: Seven Johnson LA (Eds). Metal-Binding in Medicine. Philadelphia: J.B. Lippincott Co.; 1960: pp 95-103. 1
  2. Cranton EM. Kidney effects of ethylene diamine tetraacetic acid (EDTA): a literature review. J Holistic Med 1982;4:152-157.
  3. Clarke NE, Clarke CN, Mosher RE. The “in vivo” dissolution of metastatic calcium: and approach to atherosclerosis. Am J Med Sci 1955;229:142-149.
  4. Clarke Sr. NE. Atherosclerosis, occlusive vascular disease and EDTA. Am J Cardiol 1960;6:223-236.
  5. Clarke NE, Clarke CN, Mosher RE. Treatment of angina pectoris with disodium ethylenediaminetetraacetic acid. Am J Med Sci 1956;232:654-666.
  6. ↑ Meltzer LE, Ural ME, Kitchell JR. The treatment of coronary artery disease with disodium EDTA. In: Seven JJ, Johnson LA (Eds). Metal Binding in Medicine. Philadelphia, PA: J.B. Lippincott Co.; 1960. pp 132-136.
  7. Kitchell JR, Meltzer LE. The potential uses of EDTA chelation therapy in the treatment of cardiovascular diseases. Prog Cardiovasc Dis 1961;3:338-349.
  8. Meltzer LE, Kitchell JR, Palmon F. The long term use, side effects, and toxicity of disodium ethylene diamine tetraacetic acid (EDTA). Am J Med Sci 1961;242:51-57.
  9. Seven MJ, Johnson LA (Eds). Metal-Binding in Medicine. Philadelphia: J.B. Lippincott Co.; 1960.
  10. Kitchell JR, Palmon A, Meltzer LE. The treatment of coronary artery disease with disodium EDTA – a reappraisal. Am J Cardiol 1963;11:501-506.
  11. Cranton EM, Frackelton JP. The current status of EDTA chelation therapy in the treatment of occlusive arterial disease. J Holist Med 1982;4:24-33.
  12. Diehm C, Wilhelm C, Poeschl J. Effects of EDTA-Chelation Therapy in Patients with Peripheral Vascular Disease—A Double-Blind Study. An unpublished study performed by the Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany in 1985. Presented as a paper before the International Symposium of Atherosclerosis, Melbourne, Australia, October 14,1985.
  13. Cranton EM, Frackelton JP. Scientific Rationale for EDTA Chelation Therapy in Treatment of Atherosclerosis and Diseases of Aging. 2001
  14. Carter JP. If EDTA chelation therapy is so good, why is it not more widely accepted? Journal of Advancement in Medicine 1989;2(l&2):213-226.
  15. Chappell LT. Disputes author’s conclusions on effectiveness of EDTA chelation therapy. Alternative Therapies Sep 1996;2(5):16-17.
  16. Sloth-Nielsen J, Guldager B, Mouritzen C, et al. Arteriographic findings in EDTA chelation therapy on peripheral arteriosclerosis Am J Surg 1991;162:122-125.
  17. Guldager B, Jelnes R, Jorgensen SJ, et al. EDTA treatment of intermittent claudication — a double-blind, placebo-controlled study. J Int Med 1992;231:261-267.
  18. The Committee on Scientific Dishonesty (UWU). Conclusion conceming complaints in connections with trial of EDTA versus placebo in the treatment of arteriosclerosis. Danish Research Councils.
  19. Van Rij A, Solomon C, Packer S, et al. Chelation therapy for intermittent claudication: a double-blind, randomized, controlled trial. Circulation 1994;90:1194-1199.
  20. Godfrey MD, Chappell LT. Chelation Therapy for intermittent claudication — a re-appraisal. NZ Med J 1996;109:83.
  21. McDonagh EW, Rudolph CJ, Cheraskin E. The homeostatic effect of EDTA with supportive multivitamin trace mineral supplementation upon high-density lipoproteins (HDL). J Osteopath Physicians Surgeons of California 1982;8:34.
  22. McDonagh EW, Rudolph CJ, Cheraskin E. The effect of intravenous disodium ethylene diamine tetraacetic acid (EDTA) upon blood cholesterol levels in a private practice environment. J Internat Acad Prev Med 1982;7:5-12.
  23. McDonagh EW, Rudolph CJ, Cheraskin E. The influence of EDTA salts plus multivitamin mineral therapy upon total serum cholesterol/high density lipoprotein cholesterol. Med Hypoth 1982;9:643-646.
  24. McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA salts plus supportive multivitamins-trace mineral supplementation upon renal function: a study of serum creatinine. J Holist Med 1982;4:146-151.
  25. McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA chelation therapy plus supportive multivitamin mineral supplementation upon renal function: a study in blood urea nitrogen (BUN). J Holist Med 1982;5:21-23.
  26. Cheraskin E, Wussow DG, McDonagh EW, et al. Effect of EDTA chelation and supportive multivitamin/trace mineral supplementation with and without physical activity on the heart rate. J Internat Acad Prev Med 1984;8:5-9.
  27. McDonagh EW, Rudolph CJ, Cheraskin E, et al. The effect of EDTA chelation and supportive multivitamin/trace mineral supplementation with and without physical activity upon systolic blood pressure. J Orthomol Psychiat 1984;13:1-9.
  28. McDonagh EW, Rudolph CJ, Cheraskin E. An oculocerebrovasculometric analysis of the improvement in vascular stenosis following EDTA chelation therapy. J Holist Med 1982;4:21-23.
  29. McDonagh EW, Rudolph CJ, Cheraskin E. The effect of EDTA chelation therapy plus multivitamin/trace mineral supplementation upon vascular dynamics: ankle/brachial doppler systolic blood pressure ratio, J Holist Med 1985;7:16-22.
  30. Casdorph HR, EDTA chelation therapy: efficacy in arteriosclerotic heart disease. J Holistic Med 1981;3:53-59.
  31. Casdorph HR. EDTA chelation therapy: efficacy in brain disorders. J Holistic Med 1981;3:101-117.
  32. Casdorph HR, Farr CH. Treatment of peripheral arterial occlusion, an alternative to amputation. J Holist Med 1983;5:3-15.
  33. Aronov DM. The treatment of atherosclerotic patients with calcification of the arteries with Trilon-B (disodium salt of EDTA). Klin Med 1963;41:19-23.
  34. Nikitina EK The treatment of atherosclerosis with Trilon B. Kardiologica 1972;12:137.
  35. Brucknerova O, Tulacek J. Chelates in the treatment of occlusive arteriosclerosis. Vnitrlek Lekarstri 1972;18:29-736.
  36. Olszewer E, Carter JP. EDTA chelation therapy: a retrospective study of 2,870 patients. Med Hypoth 1988;27:41-49.
  37. Olszewer E, Sabbag FC, Carter JR. A pilot double-blind study of sodium-magnesium EDTA in peripheral vascular disease. J Nat Med Assoc 1990;82:171-173.
  38. Blumer W, Cranton EM. Ninety percent reduction in cancer mortality after chelation therapy with EDTA. J Adv Med 1989;2:183-188.
  39. Chappell LT, Stahl JR. The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 1993;6:139-160.
  40. Chappell LT, Stahl JP, Evans R. EDTA chelation treatment for vascular disease: a meta-analysis using unpublished data. J Adv Med 1994,7:131-142.
  41. Sehnert KW, Clague AF, Cheraskin E. The improvement in renal function following EDTA chelation and multivitamin-trace mineral therapy; a study in creatinine clearance. Med Hypoth 1984;15:307-310.
  42. Cranton EM. Protocol of the American College for Advancement in Medicine for the safe and effective administration of EDTA chelation therapy. J Adv Med 1989;2:269-305.
  43. Rozema TC, Protocol for the Safe and Effective Administration of EDTA and Other Chelating Agents for Vascular and Degenerative Diseases. 2001
  44. Riordon HD, Cheraskin E, Dirks M, et al. Another look at renal function and the EDTA chelation treatment process. Journal of Advancement in Medicine 1989;2(l&2):263-268.
  45. Frackelton JP, Cranton EM. Monitoring Renal Function during EDTA Chelation Therapy 2001

Bibliografia

  • A Textbook on EDTA Chelation Therapy, 2nd edition, ed. by Elmer M. Cranton, M.D., Hampton Roads Publishing Company, Inc., 2001. ISBN 9781571742537
Nasze placówki
NZOZ CHEL - MED
ul. Dzika 4a, Warszawa
Rejestracja: 662 444 466
Dr Siwik: 604 450 000
Białostockie Centrum Chelatacji
ul. Rzymowskiego 43/28, Białystok
Dr Siwik: 604 450 000
NZOZ OL - MED
ul. Janowicza 30a, Olsztyn
Dr Siwik: 604 450 000
© 2013 - 2019 chelatacja.com Wszelkie prawa zastrzeżone